Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Poseida Therapeutics (PSTX – Research Report) today and set a price target of $10.00. The company’s shares closed yesterday at $2.92.
According to TipRanks, Tenthoff is an analyst with an average return of -3.8% and a 34.41% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Poseida Therapeutics, Alnylam Pharma, and Arrowhead Pharmaceuticals.
Poseida Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $14.00.
Based on Poseida Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $25 million and a GAAP net loss of $25.35 million. In comparison, last year the company earned a revenue of $10.05 million and had a GAAP net loss of $33.32 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Poseida Therapeutics (PSTX) Company Description:
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumors.
Read More on PSTX:
- Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
- Poseida Therapeutics highlights new data on lead genetic medicines programs
- William Blair views Poseida’s added collaboration with Astellas ‘favorably’
- Poseida Therapeutics Strikes Major CAR-T Therapy Collaboration Deal
- Poseida Therapeutics and Astellas Pharma to develop allogeneic cell therapies
